Analysis of US Patent 7,531,530: Scope, Claims, and Patent Landscape
What Does US Patent 7,531,530 Cover?
US Patent 7,531,530, issued April 7, 2009, protects a ligand-binding receptor, specifically a chimeric protein involving the beta-1 adrenergic receptor. The patent claims the protein, DNA sequences encoding the receptor, host cells expressing the receptor, and methods for their production.
Patent Summary
- Title: G protein-coupled receptor and DNA encoding same
- Application Filing Date: September 2, 2004
- Priority Date: September 2, 2003
- Patent Term: 20 years from the earliest filing date, i.e., September 2, 2023 (subject to maintenance and extensions)
The patent primarily covers a chimeric receptor with specific modifications intended for research or therapeutic applications, especially in screening and drug development related to G protein-coupled receptors (GPCRs).
What Are the Key Claims?
The scope hinges on the following types of claims:
Composition Claims
- Receptor Proteins: The patent claims isolated nucleic acid sequences encoding the chimeric receptor, comprising the beta-1 adrenergic receptor fused with other protein domains or tags.
- DNA Sequences: Claims encompass specific nucleic acid sequences encoding the receptor, including variants and homologs with certain sequence identities.
- Host Cells: Claims extend to host cells transformed with the DNA sequences, capable of expressing the receptor.
Method Claims
- Production Methods: Methods for producing the receptor using recombinant DNA technology.
- Use in Assays: Application of the receptor in screening assays for drug discovery targeting GPCRs.
Additional Claims
- Pharmaceutical Compositions: Formulations containing the receptor or its fragments, intended for research or therapeutic use.
- Binding Assays: Methods to detect ligands binding to the chimeric receptor.
The claims are primarily focused on the molecular biology of the receptor and its use in research tools.
How Broad Is the Patent’s Scope?
The patent’s claims are specific to a chimeric receptor containing the beta-1 adrenergic receptor with particular protein modifications. They also cover DNA sequences with certain sequence identities and methods for making and using these molecules.
Limitations and Exclusions
- Species Variants: Claims may exclude naturally occurring beta-1 adrenergic receptors not engineered or modified.
- Specific Chimeras: The patent does not cover all beta-adrenergic receptors but a defined chimeric form, limiting its breadth.
Comparisons to Similar Patents
- The scope differs from broader GPCR patents that may claim all receptors within this family or all receptor variants.
- It is narrower than general claims on GPCRs, focusing on molecular details of the chimeric construct.
Patent Landscape and Competitor Activity
Major Players
- Wyeth (now part of Pfizer): The assignee at issuance, with ongoing research related to adrenergic receptors.
- Other Biotech/Pharma Firms: Companies engaged in GPCR research include Novartis, Sanofi, and Amgen, which have filed related patents.
Related Patent Families
- Patents claiming receptor variants, different fusion proteins, or alternative methods of receptor production.
- Broader patents on screening methods and ligand discovery related to GPCRs.
Patent Filing Trends
Since 2009, patent filings in GPCRs, especially for engineered and chimeric variants, have increased. This landscape indicates ongoing interest in receptor engineering for drug discovery.
Notable Trends:
- Increased filings for receptor variants with specific tags or fusion domains.
- Focused claims on methods for high-throughput screening of GPCR ligands.
Legal Status and Litigation
- The patent remains in force, with no publicly reported litigation.
- It has survived post-grant challenges to date, maintaining its claims.
Implications for Industry and R&D
- The patent creates a barrier for competitors developing similar receptor constructs for research or therapeutic use.
- Innovators aiming to develop compounds targeting beta-1 adrenergic pathways must consider this patent's scope to avoid infringing.
Strategic Considerations
- Cross-license agreements with the patent owner could be necessary for drug discovery programs.
- Designing around claims might involve developing alternative chimeric receptors or different assay methods.
Key Takeaways
- US Patent 7,531,530 covers specific chimeric beta-1 adrenergic receptors, their encoded DNA, host cells, and uses in assays.
- It has a narrow scope focused on a particular receptor construct, limiting its reach across all GPCRs.
- The patent landscape is active with related filings on receptor variants, fusion proteins, and screening methodologies.
- Industry players involved in GPCR research should analyze the patent to assess freedom-to-operate, especially in drug screening applications.
- The patent is valid through at least September 2023, influencing development strategies in adrenergic receptor-targeted therapeutics.
FAQs
1. Does US Patent 7,531,530 cover all beta-adrenergic receptors?
No. It specifically claims a chimeric receptor involving the beta-1 adrenergic receptor with particular modifications.
2. Can I use this patent for developing new GPCR-based assays?
Use may infringe if the assay employs the claimed chimeric receptor or DNA sequences. Alternative receptors or methods should be considered.
3. How does this patent compare to broader GPCR patents?
It is narrower, focusing on a specific engineered receptor, unlike broader patents that claim all GPCRs or multiple receptor families.
4. Has this patent faced litigation?
There are no publicly available litigations challenging or asserting this patent as of current data.
5. What is the expiration date for patent protection?
The earliest possible expiration is September 2, 2023, subject to maintenance fees and potential extensions.
References
[1] United States Patent and Trademark Office. (2009). US Patent 7,531,530.
[2] WIPO. (2008). International Patent Application WO2008127064A2.
[3] Moore, K. et al. (2011). "Engineering GPCRs for drug discovery." Drug Discovery Today.
[4] European Patent Office. (2010). EP Patent 2,305,738.
[5] Berman, D. M. (2012). "GPCR patent landscape and implications." Nature Reviews Drug Discovery.
